H.I.G. Capital Completes Sale of Celerion, Highlighting a Period of Robust Exit Activity

H.I.G. Capital, a prominent global alternative investment firm, has successfully completed the sale of Celerion Holdings, Inc. to funds affiliated with THL Partners for $1.8 billion. This transaction, announced on June 15, 2026, highlights H.I.G.'s ongoing momentum in executing its Advantage strategy, which focuses on identifying and nurturing high-quality, industry-leading companies across North America.

Celerion is recognized as a leading clinical pharmacology-focused Contract Research Organization (CRO), providing essential services to pharmaceutical and biotechnology clients engaged in early-stage clinical research. With a global network of facilities, Celerion specializes in first-in-human to proof-of-concept studies, bioanalytical laboratory services, data management, and biometrics. The company’s expertise and comprehensive offerings position it as a critical partner in the pharmaceutical development process, making it an attractive acquisition target in a rapidly evolving healthcare landscape.

The sale of Celerion marks the latest in a series of successful exits from H.I.G.'s Advantage strategy, which has also included the sales of St. Croix and United Flow Technologies since the fourth quarter of 2025. Collectively, these transactions have generated over $4.5 billion in enterprise value, underscoring H.I.G.'s ability to identify differentiated businesses and execute value creation strategies effectively. This consistent track record of successful exits is indicative of H.I.G.'s operational focus and its commitment to delivering compelling returns for its investors.

The healthcare sector, particularly the CRO market, has seen significant growth in recent years, driven by increasing demand for outsourced clinical research services. As pharmaceutical and biotechnology companies seek to streamline their operations and reduce costs, partnerships with specialized CROs like Celerion have become increasingly vital. This trend is expected to continue, providing a favorable backdrop for future investments and acquisitions within the sector.

In conclusion, the acquisition of Celerion by THL Partners not only reflects the strategic alignment of both firms but also highlights the continued attractiveness of the CRO market. As H.I.G. Capital exits this investment, the firm reinforces its reputation for identifying high-potential businesses and executing successful growth strategies. The broader implications of this transaction suggest a robust outlook for the healthcare sector, particularly as companies increasingly rely on specialized partners to navigate the complexities of clinical research and drug development.